To prohibit pharmaceutical manufacturers from interfering with therapeutically equivalent or interchangeable substitution decisions by health care providers to limit competition from a generic drug or biosimilar biological product, and for other purposes.
About This Bill
Committee
Latest Action · November 1, 2022
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.